Biodexa Pharmaceticals Market Cap ($1.82 Million)
Market Cap & Net Worth: Biodexa Pharmaceticals (BDRX)
Biodexa Pharmaceticals market cap. Biodexa Pharmaceticals (NASDAQ:BDRX) has a market capitalization of $1.82 Million ($1.82 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30141 globally and #6154 in its home market, demonstrating a 561.47% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Biodexa Pharmaceticals's stock price $2.80 by its total outstanding shares 648314 (648.31K). Also see Biodexa Pharmaceticals (BDRX) cash flow conversion for how efficiently the company converts equity into cash flow.
Biodexa Pharmaceticals Market Cap History (2015–2026)
Biodexa Pharmaceticals market cap history from 2015 to 2026. Data shows change from $648.31 Billion to $1.82 Million (-69.02% CAGR). Check BDRX stock price and chart for real-time trading data and today's change.
Index Memberships
Biodexa Pharmaceticals is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.60 Trillion | 0.00% | #875 of 976 |
|
NASDAQ Composite
IXIC
|
$39.84 Trillion | 0.00% | #2792 of 3165 |
Weight: Biodexa Pharmaceticals's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Biodexa Pharmaceticals Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Biodexa Pharmaceticals's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore BDRX net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
114.01x
Biodexa Pharmaceticals's market cap is 114.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $648.31 Billion | $1.32 Million | -$6.16 Million | 490033.26x | N/A |
| 2017 | $648.31 Billion | $989.00K | -$11.71 Million | 655524.77x | N/A |
| 2018 | $200.98 Billion | $1.94 Million | -$10.37 Million | 103703.48x | N/A |
| 2019 | $89.38 Billion | $674.00K | -$10.09 Million | 132606.18x | N/A |
| 2020 | $48.49 Billion | $343.00K | -$22.19 Million | 141381.60x | N/A |
| 2021 | $27.23 Billion | $578.00K | -$5.46 Million | 47109.32x | N/A |
| 2022 | $5.11 Billion | $699.00K | -$7.66 Million | 7308.60x | N/A |
| 2023 | $43.44 Million | $381.00K | -$7.08 Million | 114.01x | N/A |
Competitor Companies of BDRX by Market Capitalization
Companies near Biodexa Pharmaceticals in the global market cap rankings as of November 4, 2026. Also see Biodexa Pharmaceticals total assets for a full breakdown of the balance sheet.
Key companies related to Biodexa Pharmaceticals by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of Biodexa Pharmaceticals (2015–2026)
Market capitalization of Biodexa Pharmaceticals from 2015 to today. Between 2015 and today, Biodexa Pharmaceticals's market cap moved from $648.31 Billion to $ 1.82 Million, with a yearly change of -69.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.82 Million | +23.35% |
| 2025 | $1.47 Million | -43.95% |
| 2024 | $2.63 Million | -93.96% |
| 2023 | $43.44 Million | -99.15% |
| 2022 | $5.11 Billion | -81.24% |
| 2021 | $27.23 Billion | -43.85% |
| 2020 | $48.49 Billion | -45.74% |
| 2019 | $89.38 Billion | -55.53% |
| 2018 | $200.98 Billion | -69.00% |
| 2017 | $648.31 Billion | 0.00% |
| 2016 | $648.31 Billion | 0.00% |
| 2015 | $648.31 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Biodexa Pharmaceticals was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.82 Million USD |
| MoneyControl | $1.82 Million USD |
| MarketWatch | $1.82 Million USD |
| marketcap.company | $1.82 Million USD |
| Reuters | $1.82 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Biodexa Pharmaceticals
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment … Read more